Results 71 to 80 of about 1,618 (187)

Current developments of gene therapy in human diseases

MedComm, Volume 5, Issue 9, September 2024.
Gene therapy has seen remarkable advancements in recent decades, demonstrating its immense potential in treating a wide range of genetic and acquired diseases. Several AAV gene therapy products have been introduced to the market, addressing various conditions.
Fanfei Liu, Ruiting Li, Zilin Zhu, Yang Yang, Fang Lu   +4 more
wiley   +1 more source

Innovative Nanotechnology in Drug Delivery Systems for Advanced Treatment of Posterior Segment Ocular Diseases

Advanced Science, Volume 11, Issue 32, August 27, 2024.
The revolutionary nanotechnology brings hope to posterior segment ocular diseases. This review delves into the challenges of conventional drug delivery and the advantages of diverse nanomaterials in enhancing drug stability, targeting, and permeability by targeting VEGF, ROS, macrophages.
Yue Wu, Xin Li, Xueyu Fu, Xiaomin Huang, Shenrong Zhang, Nan Zhao, Xiaowei Ma, Qimanguli Saiding, Mei Yang, Wei Tao, Xingtao Zhou, Jinhai Huang   +11 more
wiley   +1 more source

Concentrations of VEGF and PlGF Decrease in Eyes After Intravitreal Conbercept Injection [PDF]

Diabetes Therapy, 2018
Conbercept is a new anti-vascular endothelial growth factor drug approved for the treatment of age-related macular degeneration by the China Food and Drug Administration (CFDA) in 2013. In this study, we for the first time evaluated the concentrations of vascular endothelial growth factor (VEGF) and placental growth factor (PlGF) after patients with ...
Jun Zhou, Zheng Liu, Meng Chen, Zhi-Heng Luo, Yun-Qiu Li, Guang-Ying Qi, Tao Liu   +6 more
openaire   +2 more sources

Genome Editing VEGFA Prevents Corneal Neovascularization In Vivo

Advanced Science, Volume 11, Issue 25, July 3, 2024.
Corneal neovascularization (CNV) is a common clinical finding observed in various eye diseases, which can lead to blindness. Using the gene editing technology CRISPR/Cas9, sgRNA is selected to regulate the VEGFA gene expression that promotes neovascularization, thereby achieving therapeutic purposes.
Zhenhai Zeng, Siheng Li, Xiuhong Ye, Yiran Wang, Qinmei Wang, Zhongxing Chen, Ziqian Wang, Jun Zhang, Qing Wang, Lu Chen, Shuangzhe Zhang, Zhilin Zou, Meimin Lin, Xinyi Chen, Guoli Zhao, Colm McAlinden, Hetian Lei, Xingtao Zhou, Jinhai Huang   +18 more
wiley   +1 more source

Safety and efficacy of intravitreal injection of conbercept for the treatment of patients with choroidal neovascularization secondary to pathological myopia: Results from the SHINY study

Acta Ophthalmologica, Volume 102, Issue 4, Page e577-e586, June 2024.
Abstract Purpose To evaluate the safety and efficacy of intravitreal injections of 0.5 mg conbercept in patients with choroidal neovascularization secondary to pathological myopia (pmCNV). Methods The 177 pmCNV patients were randomly assigned in a 3:1 ratio to receive conbercept or sham injection, respectively.
Liqin Gao, Yanping Song, Xiaodong Sun, Junjun Zhang, Yuling Liu, Youxin Chen, Zhifeng Wu, Ye Jian, Xiaoling Liu, Lin Lv, Shaojun Chen, Yu‐sheng Wang, Nan Chen, Xiao Ke, Feng Zhang   +14 more
wiley   +1 more source

Effect of intravitreal conbercept treatment before vitrectomy in proliferative diabetic retinopathy

International Journal of Ophthalmology, 2018
To evaluate the safety and efficacy of intravitreal conbercept (IVC) injections as pretreatment for pars plana vitrectomy (PPV) in severe proliferative diabetic retinopathy (PDR).This was a retrospective chart review of all patients who underwent PPV for PDR from January 2014 to October 2016.
Jian-Bo Mao, Han-Fei Wu, Yi-Qi Chen, Shi-Xin Zhao, Ji-Wei Tao, Yun Zhang, Bin Zheng, Lin Wang, Li-Jun Shen   +8 more
openaire   +3 more sources

A Nucleic Acid‐Based LYTAC Plus Platform to Simultaneously Mediate Disease‐Driven Protein Downregulation

Advanced Science, Volume 11, Issue 13, April 3, 2024.
A LYTAC Plus hydrogel that combines gene silencing and protein degradation capabilities is engineered through nucleic acid self‐assembly. By simultaneously downregulating the VEGFR‐2 and ANG‐2 levels, LYTAC Plus hydrogel designed for alleviating neovascular age‐related macular degeneration (n‐AMD) shows a better therapeutic efficacy compared to the ...
Yangyang Huang, Xujiao Zhou, Yirou Zhang, Miao Xie, Fujun Wang, Jingcan Qin, Han Ye, Hong Zhang, Chuan Zhang, Jiaxu Hong   +9 more
wiley   +1 more source

Efficacy and safety of intravitreal injections of conbercept for the treatment of idiopathic choroidal neovascularization

BMC Ophthalmology
Background To determine the efficacy and safety of intravitreally injected conbercept, a vascular endothelial growth factor receptor fusion protein, for the treatment of idiopathic choroidal neovascularization (ICNV).
Gaixia Zhai, Yuanzhen Su, Shaopeng Wang, Hui Lu, Na Liu   +4 more
doaj   +1 more source

RETRACTED: Efficacy of anti‐vascular endothelial growth factor and mitomycin C on wound healing after trabeculectomy in glaucoma patients: A meta‐analysis

International Wound Journal, Volume 21, Issue 4, April 2024.
Abstract Trabeculectomy is the main surgical treatment for glaucoma, but scar formation during wound healing may lead to surgical failure. In this study, we evaluated the efficacy of anti‐vascular endothelial growth factor (anti‐VEGF) and mitomycin C (MMC) on wound healing after glaucoma surgery.
Wenlong Liu, Bang Liu
wiley   +1 more source

Effect of Conbercept Treatment on Macular Edema and Microvascular Structure in Eyes with Retinal Vein Occlusions

International Journal of General Medicine, 2022
Xiaoxia Ding, Yu Wang, Bo Zou, Dongxiao Zang, Yi Hao Department of Ophthalmology, Fushun Eye Hospital, Fushun, Liaoning, People’s Republic of ChinaCorrespondence: Xiaoxia Ding, Fushun Eye Hospital, No.
Ding X, Wang Y, Zou B, Zang D, Hao Y
doaj